Sehhoon Park

11PUBLICATIONS
54CO-AUTHORS
Molecular targetsDeep learningHaematological tumoursPredictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 03, 2024
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).

Sehhoon Park, Richard Baldry, Hyun Ae Jung

|Feb 14, 2024
Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types.

Jeanne Shen, Yoon-La Choi, Taebum Lee

|Nov 21, 2023
Prognostic significance of body mass index in small-cell lung cancer: Exploring the relationship with skeletal muscle status.

Yong Jae Kwon, Young Cheol Yoon, Hyun Su Kim

Pageof 2